Building evidence and measuring clinical outcomes for genomic medicine

[1]  Cecelia P. Tamburro,et al.  Genomic medicine for undiagnosed diseases , 2019, The Lancet.

[2]  Marc S. Williams,et al.  Pharmacogenomics , 2019, The Lancet.

[3]  R. Mägi,et al.  Recall by genotype and cascade screening for familial hypercholesterolemia in a population-based biobank from Estonia , 2018, Genetics in Medicine.

[4]  Anjali D. Zimmer,et al.  Cascade Genetic Testing of Relatives for Hereditary Cancer Risk: Results of an Online Initiative , 2018, Journal of the National Cancer Institute.

[5]  Michael J. Ackerman,et al.  Reappraisal of Reported Genes for Sudden Arrhythmic Death , 2018, Circulation.

[6]  S. Yamashita,et al.  Guidelines for Diagnosis and Treatment of Familial Hypercholesterolemia 2017 , 2018, Journal of atherosclerosis and thrombosis.

[7]  Mary E. Haas,et al.  Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations , 2018, Nature Genetics.

[8]  John J. Connolly,et al.  Harmonizing Outcomes for Genomic Medicine: Comparison of eMERGE Outcomes to ClinGen Outcome/Intervention Pairs , 2018, Healthcare.

[9]  D. Bowen,et al.  Delivery Of Cascade Screening For Hereditary Conditions: A Scoping Review Of The Literature. , 2018, Health affairs.

[10]  The 100 000 Genomes Project: bringing whole genome sequencing to the NHS , 2018, British Medical Journal.

[11]  D. Smedley,et al.  The 100 000 Genomes Project: bringing whole genome sequencing to the NHS , 2018, British Medical Journal.

[12]  Melissa L. Harry,et al.  Implementation, Adoption, and Utility of Family Health History Risk Assessment in Diverse Care Settings: evaluating implementation processes and impact with an implementation framework , 2018, Genetics in Medicine.

[13]  A. Sturm,et al.  How Can We Reach At-Risk Relatives? Efforts to Enhance Communication and Cascade Testing Uptake: a Mini-Review , 2018, Current Genetic Medicine Reports.

[14]  M. Khoury,et al.  Prevalence and Predictors of Cholesterol Screening, Awareness, and Statin Treatment Among US Adults With Familial Hypercholesterolemia or Other Forms of Severe Dyslipidemia (1999–2014) , 2018, Circulation.

[15]  Joshua C Denny,et al.  Multisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention. , 2018, JACC. Cardiovascular interventions.

[16]  John P. McCrae,et al.  Putting patients in control of data from electronic health records , 2018, British Medical Journal.

[17]  Matthew S. Lebo,et al.  Early cancer diagnoses through BRCA1/2 screening of unselected adult biobank participants , 2017, Genetics in Medicine.

[18]  E. Braunwald,et al.  Hypertrophic Cardiomyopathy: Genetics, Pathogenesis, Clinical Manifestations, Diagnosis, and Therapy. , 2017, Circulation research.

[19]  L. Mestroni,et al.  Dilated Cardiomyopathy: Genetic Determinants and Mechanisms , 2017, Circulation research.

[20]  Muin J Khoury,et al.  A proposed approach to accelerate evidence generation for genomic-based technologies in the context of a learning health system , 2017, Genetics in Medicine.

[21]  Ebony B Madden,et al.  Developing a Common Framework for Evaluating the Implementation of Genomic Medicine Interventions in Clinical Care: The IGNITE Network’s Common Measures Working Group , 2017, Genetics in Medicine.

[22]  Matthew S. Lebo,et al.  A Model for Genome-First Care: Returning Secondary Genomic Findings to Participants and Their Healthcare Providers in a Large Research Cohort , 2017, bioRxiv.

[23]  Kathryn A Phillips,et al.  Making genomic medicine evidence-based and patient-centered: a structured review and landscape analysis of comparative effectiveness research , 2017, Genetics in Medicine.

[24]  M. P. Douglas,et al.  Payer Coverage for Hereditary Cancer Panels: Barriers, Opportunities, and Implications for the Precision Medicine Initiative. , 2017, Journal of the National Comprehensive Cancer Network : JNCCN.

[25]  Dustin N. Hartzel,et al.  Genetic identification of familial hypercholesterolemia within a single U.S. health care system , 2016, Science.

[26]  W. Chung,et al.  Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2.0): a policy statement of the American College of Medical Genetics and Genomics , 2016, Genetics in Medicine.

[27]  E. Boerwinkle,et al.  Genetic Risk, Adherence to a Healthy Lifestyle, and Coronary Disease. , 2016, The New England journal of medicine.

[28]  R. Green,et al.  Aggregate penetrance of genomic variants for actionable disorders in European and African Americans , 2016, Science Translational Medicine.

[29]  Paul A. Harris,et al.  PheKB: a catalog and workflow for creating electronic phenotype algorithms for transportability , 2016, J. Am. Medical Informatics Assoc..

[30]  Manousos E. Kambouris,et al.  Test Pricing and Reimbursement in Genomic Medicine: Towards a General Strategy , 2016, Public Health Genomics.

[31]  M. Dwyer,et al.  Genetic/Familial High-Risk Assessment: Colorectal Version 1.2016, NCCN Clinical Practice Guidelines in Oncology. , 2016, Journal of the National Comprehensive Cancer Network : JNCCN.

[32]  Levi C. T. Pierce,et al.  Deep sequencing of 10,000 human genomes , 2016, Proceedings of the National Academy of Sciences.

[33]  Joseph S. Salama,et al.  Clinical Sequencing Exploratory Research Consortium: Accelerating Evidence-Based Practice of Genomic Medicine. , 2016, American journal of human genetics.

[34]  Muin J Khoury,et al.  Convergence of Implementation Science, Precision Medicine, and the Learning Health Care System: A New Model for Biomedical Research. , 2016, JAMA.

[35]  R. Green,et al.  Incorporating a Genetic Risk Score Into Coronary Heart Disease Risk Estimates: Effect on Low-Density Lipoprotein Cholesterol Levels (the MI-GENES Clinical Trial). , 2016, Circulation.

[36]  Mary Brophy,et al.  Million Veteran Program: A mega-biobank to study genetic influences on health and disease. , 2016, Journal of clinical epidemiology.

[37]  Matthew K Ito,et al.  The Agenda for Familial Hypercholesterolemia: A Scientific Statement From the American Heart Association. , 2015, Circulation.

[38]  Diane Hauser,et al.  The IGNITE network: a model for genomic medicine implementation and research , 2015, BMC Medical Genomics.

[39]  D. Ledbetter,et al.  The Geisinger MyCode Community Health Initiative: an electronic health record-linked biobank for Precision Medicine research , 2015, Genetics in Medicine.

[40]  Sarah M. Hartz,et al.  Identification of Medically Actionable Secondary Findings in the 1000 Genomes , 2015, PloS one.

[41]  L. Brooks,et al.  ClinGen--the Clinical Genome Resource. , 2015, The New England journal of medicine.

[42]  Avni Santani,et al.  Actionable exomic incidental findings in 6503 participants: challenges of variant classification , 2015, Genome research.

[43]  Harold Varmus,et al.  A new initiative on precision medicine. , 2015, New England Journal of Medicine.

[44]  Jennifer M. Taber,et al.  Information Avoidance Tendencies, Threat Management Resources, and Interest in Genetic Sequencing Feedback , 2015, Annals of behavioral medicine : a publication of the Society of Behavioral Medicine.

[45]  Magalie S Leduc,et al.  Molecular findings among patients referred for clinical whole-exome sequencing. , 2014, JAMA.

[46]  Francis S. Collins,et al.  PCORnet: turning a dream into reality , 2014, J. Am. Medical Informatics Assoc..

[47]  A. McGuire,et al.  Social and behavioral research in genomic sequencing: approaches from the Clinical Sequencing Exploratory Research Consortium Outcomes and Measures Working Group , 2014, Genetics in Medicine.

[48]  Kensaku Kawamoto,et al.  Characterizing genetic variants for clinical action , 2014, American journal of medical genetics. Part C, Seminars in medical genetics.

[49]  Deanna M. Church,et al.  ClinVar: public archive of relationships among sequence variation and human phenotype , 2013, Nucleic Acids Res..

[50]  Felix W Frueh,et al.  Regulation, reimbursement, and the long road of implementation of personalized medicine--a perspective from the United States. , 2013, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[51]  Catherine Boileau,et al.  Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease , 2013, European heart journal.

[52]  Melissa A. Basford,et al.  The Electronic Medical Records and Genomics (eMERGE) Network: past, present, and future , 2013, Genetics in Medicine.

[53]  Douglas MacFadden,et al.  SHRINE: Enabling Nationally Scalable Multi-Site Disease Studies , 2013, PloS one.

[54]  Dan M. Roden,et al.  Implementing genomic medicine in the clinic: the future is here , 2013, Genetics in Medicine.

[55]  Jennifer G. Robinson,et al.  Treatment of adults with familial hypercholesterolemia and evidence for treatment: recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. , 2011, Journal of clinical lipidology.

[56]  M. Guyer,et al.  Charting a course for genomic medicine from base pairs to bedside , 2011, Nature.

[57]  T. Marteau,et al.  Effects of communicating DNA-based disease risk estimates on risk-reducing behaviours. , 2010, The Cochrane database of systematic reviews.

[58]  Muin J. Khoury,et al.  The evidence dilemma in genomic medicine. , 2008, Health affairs.

[59]  M. Rothmund,et al.  Age‐related penetrance of endocrine tumours in multiple endocrine neoplasia type 1 (MEN1): a multicentre study of 258 gene carriers , 2007, Clinical endocrinology.

[60]  M. Eccles,et al.  Welcome to Implementation Science , 2006, Implementation Science.

[61]  R. Glasgow,et al.  Evaluating the public health impact of health promotion interventions: the RE-AIM framework. , 1999, American journal of public health.

[62]  V. Stigliano,et al.  [The Lynch syndrome]. , 1999, La Clinica terapeutica.

[63]  I. Makino.  [Diagnosis and treatment of familial hypercholesterolemia]. , 1992, [Hokkaido igaku zasshi] The Hokkaido journal of medical science.

[64]  S. Friedman,et al.  NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2017. , 2017, Journal of the National Comprehensive Cancer Network : JNCCN.

[65]  Matthew S. Lebo,et al.  The Impact of Whole-Genome Sequencing on the Primary Care and Outcomes of Healthy Adult Patients: A Pilot Randomized Trial. , 2017, Annals of internal medicine.

[66]  Yu-Chuan Li,et al.  Observational Health Data Sciences and Informatics (OHDSI): Opportunities for Observational Researchers , 2015, MedInfo.

[67]  Patrick B. Ryan,et al.  Validation of a common data model for active safety surveillance research , 2012, J. Am. Medical Informatics Assoc..

[68]  J. Haddow,et al.  Recommendations from the EGAPP Working Group: Routine testing for Factor V Leiden (R506Q) and prothrombin (20210G>A) mutations in adults with a history of idiopathic venous thromboembolism and their adult family members , 2011, Genetics in Medicine.